
Spago Nanomedical AB
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
SPAGO | ST
Overview
Corporate Details
- ISIN(s):
- SE0004899474 (+2 more)
- LEI:
- 549300DNLTVJ4OGO5X40
- Country:
- Sweden
- Address:
- Scheelevägen 22, 223 63 Lund
- Website:
- https://spagonanomedical.se/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Spago Nanomedical AB is a clinical-stage nanomedicine company developing products for the precise diagnosis and treatment of cancer and other severe diseases. The company's development is based on a proprietary platform of polymeric materials. Its portfolio includes two primary projects: Tumorad®, a targeted radionuclide therapy program, and SpagoPix, a novel MRI contrast agent. The Tumorad® candidate, 177Lu-SN201, is in Phase I/IIa clinical trials for treating advanced cancers by accumulating in tumors. The SpagoPix candidate, pegfosimer manganese, is designed to provide selective contrast enhancement in tumors and other tissues, with clinical data showing efficacy in breast cancer and endometriosis lesions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
Date | Filing | Language | Size | Actions | |
---|---|---|---|---|---|
No filings match the current criteria. |
Automate Your Workflow. Get a real-time feed of all Spago Nanomedical AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Spago Nanomedical AB via our API.
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
No insider transactions recorded for this company. |